Fetomaternal alloimmune thrombocytopenia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In '''fetomaternal alloimmune thrombocytopenia''' (also known as Neonatal Alloimmune Thrombocytopenia or NAIT) maternal IgG antibodies (specific for [[platelet]] antigens) pass through the [[placenta]] and attack platelets in the fetal circulation. This results in the fetus having low numbers of platelets and a tendency for the fetus or neonate to bruise and bleed. Medical treatment is problematic. | In '''fetomaternal alloimmune thrombocytopenia''' (also known as Neonatal Alloimmune Thrombocytopenia or NAIT) maternal IgG antibodies (specific for [[platelet]] antigens) pass through the [[placenta]] and attack platelets in the fetal circulation. This results in the fetus having low numbers of platelets and a tendency for the fetus or neonate to bruise and bleed. Medical treatment is problematic. | ||
==[[Fetomaternal alloimmune thrombocytopenia overview|Overview]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia historical perspective|Historical Perspective]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia classification|Classification]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia pathophysiology|Pathophysiology]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia causes|Causes]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia differential diagnosis|Differentiating Fetomaternal alloimmune thrombocytopenia from other Diseases]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia risk factors|Risk Factors]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia screening|Screening]]== | |||
==[[Fetomaternal alloimmune thrombocytopenia natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | |||
==Diagnosis== | |||
[[Fetomaternal alloimmune thrombocytopenia history and symptoms|History and Symptoms]] | [[Fetomaternal alloimmune thrombocytopenia physical examination|Physical Examination]] | [[Fetomaternal alloimmune thrombocytopenia laboratory findings|Laboratory Findings]] | [[Fetomaternal alloimmune thrombocytopenia other imaging findings|Other Imaging Findings]] | [[Fetomaternal alloimmune thrombocytopenia other diagnostic studies|Other Diagnostic Studies]] | |||
==Treatment== | |||
[[Fetomaternal alloimmune thrombocytopenia medical therapy|Medical Therapy]] | [[Fetomaternal alloimmune thrombocytopenia surgery|Surgery]] | [[Fetomaternal alloimmune thrombocytopenia primary prevention|Primary Prevention]] | [[Fetomaternal alloimmune thrombocytopenia secondary prevention|Secondary Prevention]] | [[Fetomaternal alloimmune thrombocytopenia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Fetomaternal alloimmune thrombocytopenia future or investigational therapies|Future or Investigational Therapies]] | |||
Revision as of 15:56, 21 September 2012
Template:Fetomaternal alloimmune thrombocytopenia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
In fetomaternal alloimmune thrombocytopenia (also known as Neonatal Alloimmune Thrombocytopenia or NAIT) maternal IgG antibodies (specific for platelet antigens) pass through the placenta and attack platelets in the fetal circulation. This results in the fetus having low numbers of platelets and a tendency for the fetus or neonate to bruise and bleed. Medical treatment is problematic.
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fetomaternal alloimmune thrombocytopenia from other Diseases
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies Template:WH Template:WikiDoc Sources